Literature DB >> 15781466

The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts.

Mario Galindo1, Jitesh Pratap, Daniel W Young, Hayk Hovhannisyan, Hee-Jeong Im, Je-Yong Choi, Jane B Lian, Janet L Stein, Gary S Stein, Andre J van Wijnen.   

Abstract

The Runx2 (CBFA1/AML3/PEBP2alphaA) transcription factor promotes skeletal cell differentiation, but it also has a novel cell growth regulatory activity in osteoblasts. We addressed here whether Runx2 activity is functionally linked to cell cycle-related mechanisms that control normal osteoblast proliferation and differentiation. We found that the levels of Runx2 gene transcription, mRNA and protein, are each up-regulated with cessation of cell growth (i.e. G(0)/G(1) transition) in preconfluent MC3T3 osteoblastic cells that do not yet express mature bone phenotypic gene expression. Cell growth regulation of Runx2 is also observed in primary calvarial osteoblasts and other osteoblastic cells with relatively normal cell growth characteristics, but not in osteosarcoma cells (e.g. SAOS-2 and ROS17/2.8). Runx2 levels are cell cycle-regulated in MC3T3 cells with respect to the G(1)/S and M/G(1) transitions: oscillates from maximal expression levels during early G(1) to minimal levels during early S phase and mitosis. However, in normal or immortalized (e.g. ATDC5) chondrocytic cells, Runx2 expression is suppressed during quiescence, and Runx2 levels are not regulated during G(1) and S phase in ATDC5 cells. Antisense or small interfering RNA-mediated reduction of the low physiological levels of Runx2 in proliferating MC3T3 cells does not accelerate cell cycle progression. However, forced expression of Runx2 suppresses proliferation of MC3T3 preosteoblasts or C2C12 mesenchymal cells which have osteogenic potential. Forced elevation of Runx2 in synchronized MC3T3 cells causes a delay in G(1). We propose that Runx2 levels and function are biologically linked to a cell growth-related G(1) transition in osteoblastic cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15781466      PMCID: PMC2895256          DOI: 10.1074/jbc.M413665200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

1.  Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia.

Authors:  S Mundlos; F Otto; C Mundlos; J B Mulliken; A S Aylsworth; S Albright; D Lindhout; W G Cole; W Henn; J H Knoll; M J Owen; R Mertelsmann; B U Zabel; B R Olsen
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

2.  Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts.

Authors:  T Komori; H Yagi; S Nomura; A Yamaguchi; K Sasaki; K Deguchi; Y Shimizu; R T Bronson; Y H Gao; M Inada; M Sato; R Okamoto; Y Kitamura; S Yoshiki; T Kishimoto
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

3.  Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development.

Authors:  F Otto; A P Thornell; T Crompton; A Denzel; K C Gilmour; I R Rosewell; G W Stamp; R S Beddington; S Mundlos; B R Olsen; P B Selby; M J Owen
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

Review 4.  Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair.

Authors:  J M Wozney; V Rosen
Journal:  Clin Orthop Relat Res       Date:  1998-01       Impact factor: 4.176

5.  Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex.

Authors:  C Banerjee; L R McCabe; J Y Choi; S W Hiebert; J L Stein; G S Stein; J B Lian
Journal:  J Cell Biochem       Date:  1997-07-01       Impact factor: 4.429

6.  Establishment and hormonal regulation of a conditionally transformed preosteocytic cell line from adult human bone.

Authors:  P V Bodine; S K Vernon; B S Komm
Journal:  Endocrinology       Date:  1996-11       Impact factor: 4.736

7.  Expression of the PEBP2alphaA/AML3/CBFA1 gene is regulated by BMP4/7 heterodimer and its overexpression suppresses type I collagen and osteocalcin gene expression in osteoblastic and nonosteoblastic mesenchymal cells.

Authors:  K Tsuji; Y Ito; M Noda
Journal:  Bone       Date:  1998-02       Impact factor: 4.398

Review 8.  Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation.

Authors:  A Alessandrini; D S Chiaur; M Pagano
Journal:  Leukemia       Date:  1997-03       Impact factor: 11.528

9.  Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements.

Authors:  A Staal; A J Van Wijnen; R K Desai; H A Pols; J C Birkenhäger; H F Deluca; D T Denhardt; J L Stein; J P Van Leeuwen; G S Stein; J B Lian
Journal:  Endocrinology       Date:  1996-05       Impact factor: 4.736

10.  MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.

Authors:  P L Puri; C Balsano; V L Burgio; P Chirillo; G Natoli; L Ricci; E Mattei; A Graessmann; M Levrero
Journal:  Oncogene       Date:  1997-03-13       Impact factor: 9.867

View more
  100 in total

1.  Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.

Authors:  Nyam-Osor Chimge; Sanjeev K Baniwal; Jingqin Luo; Simon Coetzee; Omar Khalid; Benjamin P Berman; Debu Tripathy; Matthew J Ellis; Baruch Frenkel
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

2.  Mitotic Inheritance of mRNA Facilitates Translational Activation of the Osteogenic-Lineage Commitment Factor Runx2 in Progeny of Osteoblastic Cells.

Authors:  Nelson Varela; Alejandra Aranguiz; Carlos Lizama; Hugo Sepulveda; Marcelo Antonelli; Roman Thaler; Ricardo D Moreno; Martin Montecino; Gary S Stein; Andre J van Wijnen; Mario Galindo
Journal:  J Cell Physiol       Date:  2015-09-18       Impact factor: 6.384

3.  Stress-stiffening-mediated stem-cell commitment switch in soft responsive hydrogels.

Authors:  Rajat K Das; Veronika Gocheva; Roel Hammink; Omar F Zouani; Alan E Rowan
Journal:  Nat Mater       Date:  2015-11-30       Impact factor: 43.841

4.  Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2.

Authors:  Daniel W Young; Mohammad Q Hassan; Xiao-Qing Yang; Mario Galindo; Amjad Javed; Sayyed K Zaidi; Paul Furcinitti; David Lapointe; Martin Montecino; Jane B Lian; Janet L Stein; Andre J van Wijnen; Gary S Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

5.  Overexpression of the transcriptional factor Runx2 in osteoblasts abolishes the anabolic effect of parathyroid hormone in vivo.

Authors:  Didier Merciris; Caroline Marty; Corinne Collet; Marie-Christine de Vernejoul; Valerie Geoffroy
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 6.  Transcription-factor-mediated epigenetic control of cell fate and lineage commitment.

Authors:  Gary S Stein; Sayyed K Zaidi; Janet L Stein; Jane B Lian; Andre J van Wijnen; Martin Montecino; Daniel W Young; Amjad Javed; Jitesh Pratap; Je-Yong Choi; Syed A Ali; Sandhya Pande; Mohammad Q Hassan
Journal:  Biochem Cell Biol       Date:  2009-02       Impact factor: 3.626

Review 7.  Cell cycle and developmental control of hematopoiesis by Runx1.

Authors:  Alan D Friedman
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

Review 8.  Osteosarcoma development and stem cell differentiation.

Authors:  Ni Tang; Wen-Xin Song; Jinyong Luo; Rex C Haydon; Tong-Chuan He
Journal:  Clin Orthop Relat Res       Date:  2008-06-18       Impact factor: 4.176

9.  The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells.

Authors:  Margaretha van der Deen; Jacqueline Akech; Tao Wang; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Biochem       Date:  2010-03-01       Impact factor: 4.429

10.  Hydroxyapatite nanoparticle reinforced peptide amphiphile nanomatrix enhances the osteogenic differentiation of mesenchymal stem cells by compositional ratios.

Authors:  Jeremy B Vines; Dong-Jin Lim; Joel M Anderson; Ho-Wook Jun
Journal:  Acta Biomater       Date:  2012-07-25       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.